Categories: Esports

Urs Lehmann appointed CEO of FIS

Urs Lehmann will continue his commitment to snow sports in a new role starting at the FIS Technical Committee Autumn Meetings at the end of September. The 56-year-old Swiss will become the first CEO of FIS.

- Advertisement -

“We are delighted that Urs will join the FIS leadership,” says FIS President Johan Eliasch and FIS Secretary General Michel Vion.

- Advertisement -
After the very positive development of our collaboration, we have decided to join forces in leading FIS into the future.
Urs Lehmann
Strengthening our leadership with Urs is an important step in ensuring that we are in the best possible place to tackle the major challenges that lie ahead in the coming years.
Johan Eliasch, FIS President

Urs Lehmann was an active ski racer until 1997, with the 1993 downhill world championship title in Morioka as the highlight of his career. A Doctor of Economics, he was elected President of Swiss-Ski in 2008, a position he is now stepping down from. Under Urs Lehmann’s strategic leadership, Swiss-Ski developed into a highly successful association in both sporting and economic terms. Urs Lehmann was a member of the FIS Council from 2021 to 2024. From 2009 to 2024, he was CEO of the pharmaceutical manufacturer Similasan, and since 2024 he has been Chairman of the Board of Directors of the Similasan Group.

- Advertisement -
TheNews Market

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

47 minutes ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

47 minutes ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

47 minutes ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

48 minutes ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

48 minutes ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

48 minutes ago